相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Dipeptidyl-peptidase IV inhibitor (DPP4i) confers increased odds of bullous pemphigoid even years after drug initiation
Khalaf Kridin et al.
ARCHIVES OF DERMATOLOGICAL RESEARCH (2023)
DPP-4 inhibitors for treating T2DM-hype or hope? an analysis based on the current literature
Kunika Saini et al.
FRONTIERS IN MOLECULAR BIOSCIENCES (2023)
Pyrazole scaffold-based derivatives: A glimpse of α-glucosidase inhibitory activity, SAR, and route of synthesis
Jannat ul Firdaus et al.
ARCHIV DER PHARMAZIE (2023)
Pancreatic safety of DPP-4 inhibitors in type 2 diabetes millitus A protocol for systematic review and network meta-analysis
Fan Yang et al.
MEDICINE (2022)
Association between use of sodium-glucose cotransporter 2 inhibitors, glucagon-like peptide 1 agonists, and dipeptidyl peptidase 4 inhibitors with kidney outcomes in patients with type 2 diabetes: A systematic review and network meta-analysis
Shuo Yang et al.
PLOS ONE (2022)
Suspected adverse drug reactions of the type 2 antidiabetic drug class dipeptidyl-peptidase IV inhibitors (DPP4i): Can polypharmacology help explain?
Lauren Jones et al.
PHARMACOLOGY RESEARCH & PERSPECTIVES (2022)
Dipeptidyl peptidase-4 inhibitors and gallbladder or biliary disease in type 2 diabetes: systematic review and pairwise and network meta-analysis of randomised controlled trials
Liyun He et al.
BMJ-BRITISH MEDICAL JOURNAL (2022)
Design, Synthesis and SAR Studies of Novel and Potent Dipeptidyl Peptidase 4 Inhibitors
Na Luo et al.
CHINESE JOURNAL OF CHEMISTRY (2021)
Pharmaceutical Drugs and Natural Therapeutic Products for the Treatment of Type 2 Diabetes Mellitus
Jana Blahova et al.
PHARMACEUTICALS (2021)
Identification and structureeactivity relationship exploration of uracil-based benzoic acid and ester derivatives as novel dipeptidyl Peptidase-4 inhibitors for the treatment of type 2 diabetes mellitus
Qing Li et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2021)
Novel Potent and Selective DPP-4 Inhibitors: Design, Synthesis and Molecular Docking Study of Dihydropyrimidine Phthalimide Hybrids
Ahmed A. E. Mourad et al.
PHARMACEUTICALS (2021)
GPR119 agonists: Novel therapeutic agents for type 2 diabetes mellitus
Ajay Manaithiya et al.
BIOORGANIC CHEMISTRY (2021)
A review upon medicinal perspective and designing rationale of DPP-4 inhibitors
Shubham Kumar et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2021)
Design, synthesis and biological evaluation of glycolamide, glycinamide, and β-amino carbonyl 1,2,4-triazole derivatives as DPP-4 inhibitors
Mao-Tsu Fuh et al.
BIOORGANIC CHEMISTRY (2021)
Structure-Activity Relationship Analysis of Cocrystallized Gliptin-like Pyrrolidine, Trifluorophenyl, and Pyrimidine-2,4-Dione Dipeptidyl Peptidase-4 Inhibitors
Katarina Tomovic et al.
JOURNAL OF MEDICINAL CHEMISTRY (2021)
New quinoxaline compounds as DPP-4 inhibitors and hypoglycemics: design, synthesis, computational and bio-distribution studies
Yasmin M. Syam et al.
RSC ADVANCES (2021)
Design and synthesis of tetrahydropyridopyrimidine derivatives as dual GPR119 and DPP-4 modulators
Yuanying Fang et al.
BIOORGANIC CHEMISTRY (2020)
Design, Synthesis, and Evaluation of a Series of Novel Super Long-Acting DPP-4 Inhibitors for the Treatment of Type 2 Diabetes
Chen Zhang et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
Pyrazole Incorporated New Thiosemicarbazones: Design, Synthesis and Investigation of DPP-4 Inhibitory Effects
Belgin Sever et al.
MOLECULES (2020)
Design, synthesis and biological evaluation of novel 1,2,3-triazole-based xanthine derivatives as DPP-4 inhibitors
Sirassu Narsimha et al.
JOURNAL OF CHEMICAL SCIENCES (2020)
Design, Synthesis and Biological Evaluation of Spiro Cyclohexane-1,2-Quinazoline Derivatives as Potent Dipeptidyl Peptidase IV Inhibitors
Yasmin M. Syam et al.
MINI-REVIEWS IN MEDICINAL CHEMISTRY (2019)
The Role of DPP-4 Inhibitors in the Treatment Algorithm of Type 2 Diabetes Mellitus: When to Select, What to Expect
Konstantinos Makrilakis
INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH (2019)
Hydrolytic Metabolism of Cyanopyrrolidine DPP-4 Inhibitors Mediated by Dipeptidyl Peptidases
Fandi Kong et al.
DRUG METABOLISM AND DISPOSITION (2019)
Fibroblast activation protein is dispensable for control of glucose homeostasis and body weight in mice
Brandon L. Panaro et al.
MOLECULAR METABOLISM (2019)
Facile new industrial process for synthesis of teneligliptin through new intermediates and its optimization with control of impurities
Neeraj Kumar et al.
RESEARCH ON CHEMICAL INTERMEDIATES (2018)
Design, synthesis and biological evaluation of novel pyrimidinedione derivatives as DPP-4 inhibitors
Ning Li et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2018)
Recent progress of the development of dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes mellitus
Ning Li et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2018)
Diabetic Cardiomyopathy: Current and Future Therapies. Beyond Glycemic Control
Giulia Borghetti et al.
FRONTIERS IN PHYSIOLOGY (2018)
Asymmetric Formal Synthesis of the Long-Acting DPP-4 Inhibitor Omarigliptin
Feng Peng et al.
JOURNAL OF ORGANIC CHEMISTRY (2017)
New Dipeptidyl Peptidase 4 Inhibitors among Adamantane Derivatives
A. A. Spasov et al.
RUSSIAN JOURNAL OF BIOORGANIC CHEMISTRY (2017)
A concise and efficient synthesis of vildagliptin
Michele Castaldi et al.
TETRAHEDRON LETTERS (2017)
Discovery of triazole-based uracil derivatives bearing amide moieties as novel dipeptidyl peptidase-IV inhibitors
Xiaoyan Deng et al.
BIOORGANIC CHEMISTRY (2017)
The mechanisms of action of metformin
Graham Rena et al.
DIABETOLOGIA (2017)
Synthesis of phenylpyridine derivatives and their biological evaluation toward dipeptidyl peptidase-4
Yan Zhu et al.
CHEMISTRY OF HETEROCYCLIC COMPOUNDS (2017)
Comparative Binding Analysis of Dipeptidyl Peptidase IV (DPP-4) with Antidiabetic Drugs - An Ab Initio Fragment Molecular Orbital Study
Sundaram Arulmozhiraja et al.
PLOS ONE (2016)
Discovery of Novel Tricyclic Heterocycles as Potent and Selective DPP-4 Inhibitors for the Treatment of Type 2 Diabetes
Wen-Lian Wu et al.
ACS MEDICINAL CHEMISTRY LETTERS (2016)
Design, Synthesis and Biological Evaluation of Imidazo[1,2-a]pyridine Derivatives as Novel DPP-4 Inhibitors
Qing Li et al.
CHEMICAL BIOLOGY & DRUG DESIGN (2015)
Clinical pharmacology of dipeptidyl peptidase 4 inhibitors indicated for the treatment of type 2 diabetes mellitus
Xiao-Wu Chen et al.
CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY (2015)
Anagliptin, a potent dipeptidyl peptidase IV inhibitor: its single-crystal structure and enzyme interactions
Yukihisa S. Watanabe et al.
JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY (2015)
Evolution of a Manufacturing Route to Omarigliptin, A Long-Acting DPP-4 Inhibitor for the Treatment of Type 2 Diabetes
John Y. L. Chung et al.
ORGANIC PROCESS RESEARCH & DEVELOPMENT (2015)
Synthesis of Vildagliptin Utilizing Continuous Flow and Batch Technologies
Laurent Pellegatti et al.
ORGANIC PROCESS RESEARCH & DEVELOPMENT (2015)
Design, Synthesis, and Pharmacological Evaluation of Fused β-Homophenylalanine Derivatives as Potent DPP-4 Inhibitors
Tao Jiang et al.
ACS MEDICINAL CHEMISTRY LETTERS (2015)
Synthesis of New DPP-4 Inhibitors Based on a Novel Tricyclic Scaffold
Carolin Schwehm et al.
ACS MEDICINAL CHEMISTRY LETTERS (2015)
Sixteen-Years of Clinically Relevant Dipeptidyl Peptidase-IV(DPP-IV) Inhibitors for Treatment of Type-2 Diabetes: A Perspective
R. N. Kushwaha et al.
CURRENT MEDICINAL CHEMISTRY (2014)
Pleiotropic Mechanisms for the Glucose-Lowering Action of DPP-4 Inhibitors
Bilal Omar et al.
DIABETES (2014)
Recent approaches to medicinal chemistry and therapeutic potential of dipeptidyl peptidase-4 (DPP-4) inhibitors
Bhumika D. Patel et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2014)
Antimicrobial and Hypoglycemic Activities of Novel N-Mannich Bases Derived from 5-(1-Adamantyl)-4-substituted-1,2,4-triazoline-3-thiones
Ebtehal S. Al-Abdullah et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2014)
Dipeptidyl Peptidase IV and Its Inhibitors: Therapeutics for Type 2 Diabetes and What Else?
Lucienne Juillerat-Jeanneret
JOURNAL OF MEDICINAL CHEMISTRY (2014)
Omarigliptin (MK-3102): A Novel Long-Acting DPP-4 Inhibitor for Once-Weekly Treatment of Type 2 Diabetes
Tesfaye Biftu et al.
JOURNAL OF MEDICINAL CHEMISTRY (2014)
Discovery of Imigliptin, a Novel Selective DPP-4 Inhibitor for the Treatment of Type 2 Diabetes
Chutian Shu et al.
ACS MEDICINAL CHEMISTRY LETTERS (2014)
The role of nateglinide and repaglinide, derivatives of meglitinide, in the treatment of type 2 diabetes mellitus
Rodolfo Guardado-Mendoza et al.
ARCHIVES OF MEDICAL SCIENCE (2013)
A comparative study of the binding modes of recently launched dipeptidyl peptidase IV inhibitors in the active site
Mika Nabeno et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2013)
Synthesis, Evaluation and Molecular Docking of Prolyl-Fluoropyrrolidine Derivatives as Dipeptidyl Peptidase IV Inhibitors
Mani Sharma et al.
CHEMICAL BIOLOGY & DRUG DESIGN (2013)
Principles and Applications of Halogen Bonding in Medicinal Chemistry and Chemical Biology
Rainer Wilcken et al.
JOURNAL OF MEDICINAL CHEMISTRY (2013)
Synthesis, Structure-Activity Relationship, and Pharmacophore Modeling Studies of Pyrazole-3-Carbohydrazone Derivatives as Dipeptidyl Peptidase IV Inhibitors
Deyan Wu et al.
CHEMICAL BIOLOGY & DRUG DESIGN (2012)
Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis
C. F. Deacon et al.
DIABETES OBESITY & METABOLISM (2012)
Berry components inhibit α-glucosidase in vitro: Synergies between acarbose and polyphenols from black currant and rowanberry
Ashley S. Boath et al.
FOOD CHEMISTRY (2012)
Physiological and Pharmacological Mechanisms through which the DPP-4 Inhibitor Sitagliptin Regulates Glycemia in Mice
Aurelie Waget et al.
ENDOCRINOLOGY (2011)
Inhibition of DPP-4 with Vildagliptin Improved Insulin Secretion in Response to Oral as well as Isoglycemic Intravenous Glucose without Numerically Changing the Incretin Effect in Patients with Type 2 Diabetes
Irfan Vardarli et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2011)
Synthesis and SAR of azolopyrimidines as potent and selective dipeptidyl peptidase-4 (DPP4) inhibitors for type 2 diabetes
Robert P. Brigance et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2010)
Effect of Endogenous GLP-1 on Insulin Secretion in Type 2 Diabetes
Marzieh Salehi et al.
DIABETES (2010)
Highly Efficient Asymmetric Synthesis of Sitagliptin
Karl B. Hansen et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2009)
Preparation of Saxagliptin, a Novel DPP-IV Inhibitor
Scott A. Savage et al.
ORGANIC PROCESS RESEARCH & DEVELOPMENT (2009)
Synthesis of (S)-1-(2-chloroacetyl)pyrrolidine-2-carbonitrile:: A key intermediate for dipeptidyl peptidase IV inhibitors
Santosh K. Singh et al.
BEILSTEIN JOURNAL OF ORGANIC CHEMISTRY (2008)
Discovery of new binding elements in DPP-4 inhibition and their applications in novel DPP-4 inhibitor design
Gui-Bai Liang et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2008)
Structure-based design and synthesis of benzimidazole derivatives as dipeptidyl peptidase IV inhibitors
Michael B. Wallace et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2008)
Involvement of DPP-IV catalytic residues in enzyme-saxagliptin complex formation
William J. Metzler et al.
PROTEIN SCIENCE (2008)
Dipeptidyl peptidase-IV inhibitors: a major new class of oral antidiabetic drug
Iskandar Idris et al.
DIABETES OBESITY & METABOLISM (2007)
(2R)-4-Oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-α]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine:: A potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes
D Kim et al.
JOURNAL OF MEDICINAL CHEMISTRY (2005)
Crystal structure of human dipeptidyl peptidase IV in complex with a decapeptide reveals details on substrate specificity and tetrahedral intermediate formation
K Aertgeerts et al.
PROTEIN SCIENCE (2004)
GLP-1 receptor agonists and DPP-4 inhibitors in the treatment of type 2 diabetes
B Ahrén et al.
HORMONE AND METABOLIC RESEARCH (2004)
1-[[(3-hydroxy-1-adamantyl)amino]acetyl]-2-cyano-(S)-pyrrolidine:: A potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties
EB Villhauer et al.
JOURNAL OF MEDICINAL CHEMISTRY (2003)
分享论文
